Disc Medicine, Inc. (IRON) News
Track canonical SquawkNews coverage tagged to IRON, Disc Medicine, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IRON: Promising data and efficient trial execution position both DISC-3405 and bitopertin for strong market entry
DISC-3405 shows promising efficacy and safety in PV, with rapid trial progress and potential for frontline use. Bitopertin's APOLLO phase III trial is well-powered and targets a rare disease market, with launch strategie
EQUITY | Sep 10, 2026, 01:14 PM UTC
L
Disc Medicine Price Target Maintained With a $100.00/Share by Wedbush
Ratings actions from Benzinga
EQUITY | Sep 10, 2026, 01:12 PM UTC
M
Disc Medicine reports Phase 2 DISC-3405 data from RESTORE-PV
Disc Medicine said initial Phase 2 RESTORE-PV data showed DISC-3405 controlled hematocrit and markedly reduced phlebotomy events.
EQUITY | Sep 10, 2026, 12:53 PM UTC
L
IRON: Promising late-stage data and strong market potential position both programs for significant impact
DISC-3405 shows promising efficacy and safety in PV, with plans for phase III and potential as a frontline therapy. Bitopertin's APOLLO phase III trial is well-powered, targeting a rare disease with significant unmet nee
EQUITY | Sep 10, 2026, 12:48 PM UTC
L
IRON - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of H
IRON - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
EQUITY | Sep 09, 2026, 11:25 PM UTC
L
IRON seen with multiple late-stage catalysts across hematology programs
TradingView reports upcoming late-stage catalysts for IRON, including phase III data for a bitopertin program in porphyria; Selcodebart data in myelofibrosis; and first patient data for DISC-3405 in polycythemia vera.
EQUITY | Sep 09, 2026, 02:29 PM UTC
M
Iron-focused red blood cell trial data and therapies eyed for catalysts
Bitopertin phase III data for red blood cell disorders is expected soon, with additional polycythemia vera data planned for SOHO. Expanded access and launch plans are underway.
EQUITY | Sep 09, 2026, 01:35 PM UTC
L
Disc Medicine maintained at Outperform by Wedbush
Wedbush maintained a Outperform rating on Disc Medicine, according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 12:47 PM UTC
L
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. NASDAQ:IRON, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patien
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
IRON - Disc Medicine to Participate in Upcoming Investor Conferences
IRON - Disc Medicine to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
IRON - Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - C
IRON - Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
EQUITY | Aug 31, 2026, 10:07 PM UTC
H
Truist Reiterates Buy On IRON
Truist reiterates buy rating on IRON
EQUITY | Jul 31, 2026, 01:00 PM UTC
M
IRON Disc Medicine Ends Q2 With $717.7M Cash
IRON Disc Medicine has $717.7M in cash and securities
EQUITY | Jul 30, 2026, 12:37 PM UTC
L
IRON - Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
IRON - Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Jul 30, 2026, 12:31 PM UTC
L
IRON Disc Medicine RESULTS: Q2, Q2 basic EPS $-1.54 vs. EST $-1.75, Q2 operating expenses $65.075M, Q2 Operating Income $-65.075M vs. EST $
IRON Disc Medicine RESULTS: Q2, Q2 basic EPS $-1.54 vs. EST $-1.75, Q2 operating expenses $65.075M, Q2 Operating Income $-65.075M vs. EST $-71M, Q2 Net Income $-59.532M vs. EST $-68.2M
EARNINGS | Jul 30, 2026, 12:31 PM UTC
L
Disc Medicine Insider Sold Shares Worth $2,473,780, According to a Recent SEC Filing
() -- John D Quisel, Director and Chief Executive Officer, on July 13, 2026, sold 33,000 shares in Disc Medicine (IRON) for $2,473,780. Following the Form 4 filing with the SEC, Quisel has control over a total of 226,064
REGULATION | Jul 15, 2026, 08:05 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC